Rifampin, a useful drug for nonmycobacterial infections

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 345-357

  Vesely, Josef J K ^a,b   Pien, Francis D ^a,b,c   Pien, Brian C T ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b STRAUB CLINIC AND HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

AREA UNDER THE CURVE; BACTERIAL INFECTION; BRUCELLA; CHLAMYDIA TRACHOMATIS; DROWSINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS DUCREYI; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; LEGIONELLA PNEUMOPHILA; NEISSERIA GONORRHOEAE; PRURITUS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; THROMBOCYTOPENIC PURPURA; VERTIGO;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL INFECTIONS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HAEMOPHILUS INFECTIONS; HUMANS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 0031918978     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (165)

1. Morris AB, Brown RB, Sands M. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother 1993;37:1-7.
2. Sensi P. Rifamycins. In: Kuemmerle HP, ed. Clinical chemotherapy, vol 2. New York: Thieme-Stratton, 1983:189-205.
3. Liggett SB, Berger JR, Hush J. Cerebrospinal fluid xanthochromia with rifampin. Ann Neurol 1982;12:228-9.
4. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 1981;12:159-218.
5. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992;29:719-24.
6. Nitti V, Virgilio R, Patricolo MR, Iuliano A. Pharmacokinetic study of intravenous rifampicin. Chemotherapy 1977;23:1-6.
7. Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. Ther Drug Monit 1986;8:11-16.
8. Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit 1986;8:17-22.
9. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tubercle Lung Dis 1995;76:109-13.
10. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
11. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983;5(suppl 3):428-32.
12. Advenier C, Gobert C, Houin G, Bidet D, Richelet S, Tillement JP. Pharmacokinetic studies of rifampicin in the elderly. Ther Drug Monit 1983;5:61-5.
13. Snider DE Jr, Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980;122:65-79.
14. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5(suppl 3):440-6.
15. Tahan SR, Diamond JR, Blank JM, Horan RF. Acute hemolysis and renal failure with rifampicin-dependent antibodies after discontinuous administration. Transfusion 1985;25:124-7.
16. Martinez E, Muniz E, Domingo P. Evidence implicating rifampin-independent antiplatelet antibodies in the pathogenesis of rifampin-induced immune thrombocytopenia. Clin Infect Dis 1994;19:351-3.
17. Bansal VK, Bennett D, Molnar Z. Prolonged renal failure after rifampin. Am Rev Respir Dis 1977;116:137-40.
18. Katz MD, Lor E. Acute interstitial nephritis associated with intermittent rifampin use. Drug Intell Clin Pharm 1986;20:789-81.
19. Graber CD, Jebaily J, Galphin RL, Doering E. Light chain proteinuria and humoral immunoincompetence in tuberculous patients treated with rifampin. Am Rev Respir Dis 1973;107:713-17.
20. Soffer O, Nassar VH, Campbell WG, Bourke E. Light chain cast nephropathy and acute renal failure associated with rifampin therapy. Am J Med 1987;82:1052-6.
21. Harland RW, Lindblom SS, Munnell MO. Anaphylaxis from rifampin. Am J Med 1992;92:581-2.
22. Tajima A, Mine T, Ogata E. Rifampicin-associated ulcerative colitis. Ann Intern Med 1992;116:778.
23. Pratt TH. Rifampin-induced organic brain syndrome. JAMA 1979;241:2421-2.
24. Takasu N, Yamada T, Miura H, et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis 1982;125:23-7.
25. Benedetti MS, Dostert P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994;102(suppl 9):101-5.
26. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984;144:1667-71.
27. Baciewicz AM, Self TH, Bekemeyer WB. Update on rifampin drug interactions. Arch Intern Med 1987;147:565-8.
28. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions. II. Arch Intern Med 1992;152: 711-16.
29. Brockmeyer NH, Mertins L, Klimek K, Goos M, Ohnhaus EE. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol 1990;28:387-93.
30. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993;37:1426-31.
31. Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions III. Arch Intern Med 1997;157:2453-8.
32. Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-50.
33. Doble N, Shaw R, Rowland-Hill C, Lush M, Warnock DW, Keal EE. Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J Antimicrob Chemother 1988;21:633-5.
34. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358-61.
35. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983;5(suppl 3):407-11.
36. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988;202:45-58.
37. Hui J, Gordon N, Kajioka R. Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother 1977;11: 773-9.
38. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(suppl A):37-46.
39. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
40. Gudmundsson S, Erlendsdottir H, Gottfredsson M, Gudmundsson A. The postantibiotic effect induced by antimicrobial combinations. Scand J Infect Dis 1991;suppl 74:80-93.
41. Schmitt DD, Edmiston CE, Krepel C, et al. Impact of postantibiotic effect on bacterial adherence to vascular prostheses. J Surg Res 1990;48:373-8.
42. Farr BA. Rifamycins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:317-29.
43. Craig WA. Rifampin and related drugs. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992:265-6.
44. Karchmer AW. Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am J Med 1985;78(suppl 6B):116-27.
45. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988;109:619-24.
46. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided Staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996;101:68-76.
47. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
48. Roth B. Penetration of parenterally administered rifampicin into bone tissue. Chemotherapy 1984;30:358-65.
49. Cluzel RA, Lopitaux R, Sirot J, Rampon S. Rifampicin in the treatment of osteoarticular infections due to staphylococci. J Antimicrob Chemother 1984;13(suppl C):23-9.
50. Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987;82(suppl 4A):73-5.
51. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51.
52. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20.
53. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-6.
54. Scully BE, Briones F, Gu JW, Neu HC. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med 1992;152:353-6.
55. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996;156:1109-12.
56. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811-13.
57. Dos Santos KR, Fonseca LS, Filho PPG. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996;17:813-16.
58. Wheat LJ, Kohler RB, White AL, White A. Effect of rifampin on nasal carriers of coagulase-positive staphylococci. J Infect Dis 1981;144:177.
59. McAnally TP, Lewis MR, Brown DR. Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother 1984;25:422-6.
60. Hoss DM, Feder HM. Addition of rifampin to conventional therapy for recurrent furunculosis. Arch Dermatol 1995;131:647-8.
61. Fidalgo S, Vazquez F, Mendoza MC, Perez F, Mendez FJ. Bacteremia due to Staphylococcus epidermidis: microbiologic, epidemiologic, clinical, and prognostic features. Rev Infect Dis 1990;12:520-8.
62. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994;38:2231-7.
63. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologie and clinical observations as guides to therapy. Ann Intern Med 1983;98:447-55.
64. Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983;5(suppl 3):533-7
65. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoalt D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39:235-40.
66. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992;14:1251-3.
67. Goeau-Brissonniere O, Mercier F, Nicolas MH, et al. Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994;19:739-41.
68. Freyrie A, Curti T, Rodio M, et al. Interaction between vascular prostheses and rifampicin in the prevention of the grafts infection. An experimental study. Int Angiol 1992;11:113-16.
69. Avramovic J, Fletcher JP. Prevention of prosthetic vascular graft infection by rifampicin impregnation of a protein-sealed Dacron graft in combination with parenteral cephalosporin. J Cardiovasc Surg 1992;33:70-4.
70. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Ann Intern Med 1997;127:267-74.
71. Garrison JR, Henke PK, Smith KR, et al. In vitro and in vivo effects of rifampin on Staphylococcus epidermidis graft infections. Am Soc Artif Intern Organs J 1997;43:8-12.
72. Gilbert GL, MacInnes SJ, Guise IA. Rifampin prophylaxis for throat carriage of Haemophilus influenzae type b in patients with invasive disease and their contacts. BMJ 1991;302: 1432-5.
73. Horner DB, McCracken GH Jr, Ginsburg CM, Zweighaft TC. A comparison of three antibiotic regimens for eradication of Haemophilus influenzae type B from the pharynx of infants and children. Pediatrics 1980;66:136-8.
74. Isaacs D, Person M, Gilbert GL, Grimwood K, McIntyre P. Royal Australasian College of Physicians position paper. Chemoprophylaxis for Haemophilus and meningococcal infections. J Paediatr Child Health 1994;30:9-11.
75. Green M, Li KI, Wald ER, Guerra N, Byers C, Duration of rifampin Chemoprophylaxis for contacts of patients infected with Haemophilus influenzae type b. Antimicrob Agents Chemother 1992;36:545-7.
76. Cuevas LE, Kazembe P, Mughogho GK, Tillotson GS, Hart CA. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J Infect Dis 1995;171:728-31.
77. Drew TM, Altman R, Black K, Goldfield M. Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients. J Infect Dis 1976;133:194-8.
78. Yagupsky P, Ashikenazi S, Block C. Rifampicin-resistant meningococci causing invasive disease and failure of Chemoprophylaxis. Lancet 1993;341:1152-3.
79. Abadi FJR, Carter PE, Cash P, Pennington TH. Rifampin resistance in Neisseria meningitidis due to alterations in membrane permeability. Antimicrob Agents Chemother 1996;40:646-51.
80. Edelstein PH. Legionnaires' disease. Clin Infect Dis 1993;16:741-9.
81. Stout JE, Yu V. Legionellosis. N Eng J Med 1997;337:682-7.
82. Fu KP, Neu HC. Inactivation of β-lactam antibiotics by Legionella pneumophila. Antimicrob Agents Chemother 1979;16:561-4.
83. Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: a review. Clin Infect Dis 1995;21(suppl 3):S265-76.
84. Barker JE, Farrell ID. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies. J Antimicrob Chemother 1990;26:45-53.
85. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995;39:1561-6.
86. Kitsukawa K, Hara J, Saito A. Inhibition of Legioneila pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents. J Antimicrob Chemother 1991;27:343-53.
87. Brook I. Beta-lactamase producing bacteria recovered after clinical failures with various penicillin therapy. Arch Otolaryngol 1984;110:228-31.
88. Chaudhary S, Bilinsky SA, Hennessy JL, et al. Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr 1985;106:481-5.
89. Tanz RR, Shulman ST, Barthel MJ, Willen C, Yogev R. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr 1985;106:876-80.
90. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377-82.
91. Friedland IR. Therapy of penicillin- and cephalosporin-resistant pneumococcal infections. Ann Med 1993;25:451-5.
92. Mason EO Jr, Kaplan SL, Lamberth LB, Tillman J. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use. Antimicrob Agents Chemother 1992;36:1703-7.
93. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992;166:1346-53.
94. Paris MM, Hickey SM, Uscher MI, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38:1320-4.
95. Peters MJ, Pizer BL, Millar M. Rifampicin in pneumococcal meningoencephalitis. Arch Dis Child 1994;71:77-9.
96. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995;39:1988-92.
97. Quagliarello VJ, Scheid WM. Treatment of bacterial meningitis. N Engl J Med 1997;336:708-16.
98. Paris MM, Ramilo O, McCracken GH Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995;39:2171-5.
99. Garcia-Arenzana JM, Montes M, Perez-Trallero E. Are rifampin-resistant Streptococcus pneumoniae strains a consequence of the increase in cases of tuberculosis? Clin Infect Dis 1994;19:360.
100. Mortensen JE, Moore DG, Clarridge JE, Young EJ. Antimicrobial susceptibility of clinical isolates of Brucella. Diagn Microbiol Infect Dis 1986;5:163-9.
101. Khuri-Bulos NA, Daoud AH, Azab SM. Treatment of childhood brucellosis: results of a prospective trial on 113 children. Pediatr Infect Dis J 1993;12:377-81.
102. Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother 1989;23:433-9.
103. Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. Ann Intern Med 1992;117:25-30.
104. Montejo JM, Alberola I, Glez-Zarate P, et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993;16:671-6.
105. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990;12:1060-99.
106. Colmenero JD, Fernandez-Gallardo LC, Agundez JAG, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother 1994;38:2798-802.
107. Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993;37:1831-4.
108. Lang R, Rubinstein E. Quinolones for the treatment of brucellosis. J Antimicrob Chemother.1992;29:357-63.
109. Adal KA, Cockerell CJ, Petri WA Jr. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea. N Engl J Med 1994;330:1509-15.
110. Jackson LA, Perkins BA, Wenger JD. Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health 1993;83:1707-11.
111. Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992;11:474-8.
112. Maguina C, Gotuzzo E. Treatment of bartonellosis. J Travel Med 1995;2:278.
113. Marrie TJ. Coxiella burnetii (Q fever) pneumonia. Clin Infect Dis 1995;21(suppl 3):S253-64.
114. Bental T, Fejgin M, Keysary A, et al. Chronic Q fever of pregnancy presenting as Coxiella burnetii placentitis: successful outcome following therapy with erythromycin and rifampin. Clin Infect Dis 1995;21:1318-21.
115. Siegman-Igra Y, Kaufman O, Keysary A, Rzotkiewicz S, Shalit I. Q fever endocarditis in Israel and a worldwide review. Scand J Infect Dis 1997;29:41-9.
116. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother 1992;36: 2799-803.
117. Klein MB, Nelson CM, Goodman JL. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother 1997;41:76-9.
118. Dumler JS, Bakken JS. Ehrlichial diseases of humans: emerging tick-borne infections. Clin Infect Dis 1995;20: 1102-10.
119. Prescott JF. Rhodococcus equi: an animal and human pathogen. Clin Microbiol Rev 1991;4:20-34.
120. Verville TD, Huycke MM, Greenfield RA, Fine DP, Kuhls TL, Slater LN. Rhodococcus equi infections of humans: 12 cases and a review of the literature. Medicine 1994;73: 119-32.
121. Harvey RL, Sunstrum JC. Rhodococcus equi infections in patients with and without human immunodeficiency virus infection. Rev Infect Dis 1991;13:139-45.
122. Nordmann P, Ronco E. In vitro antimicrobial susceptibility of Rhodococcus equi. J Antimicrob Chemother 1992;29:383-93.
123. Linder R. Rhodococcus equi and Arcanobacterium haemolyticum: two "coryneform" bacteria increasingly recognized as agents of human infection. Emerging Infect Dis 1997;3:145-53.
124. Takai S, Takeda K, Nakano Y, et al. Emergence of rifampin-resistant Rhodococcus equi in an infected foal. J Clin Microbiol 1997;35:1904-8.
125. Acar JF, Goldstein FW, Duval J. Use of rifampin for the treatment of serious staphylococcal and gram-negative bacillary infections. Rev Infect Dis 1983;5(suppl 3):S502-6.
126. Rubin J, Stoehr G, Yu VL, Muder RR, Matador A, Kamerer DB. Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. Arch Otolaryngol Head Neck Surg 1989;115:1063-9.
127. Chin NX, Neu HC. Synergy of imipenem, a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. Chemotherapy 1987;33:183-8.
128. Xiong YQ, Caillon J, Drugeon H, Potel G, Baron D. The effect of rifampicin on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. J Antimicrob Chemother 1996;37:993-8.
129. Zuravleff JJ, Chervenick P, Yu VL, Muder RR, Diven WF. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med 1984;103:878-85.
130. Yu VL, Zuravleff JJ, Peacock JE, DeHertogh D, Tashjian L. Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients. Antimicrob Agents Chemother 1984;26:575-7.
131. Korvick JA, Peacock JE Jr, Muder RR, Wheeler RR, Yu VL. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother 1992;36:620-5.
132. Chandrika T, Adler SP. A case of neonatal meningitis due to Flavobacterium meningosepticum successfully treated with rifampin. Pediatr Infect Dis 1982;1:40-1.
133. Winslow DL, Pankey GA. Successful therapy with rifampin - Flavobacterium meningosepticum meningitis developing while on erythromycin therapy. Del Med J 1982;54:575-9.
134. Hirsh BE, Wong B, Kiehn TE, Gee T, Armstrong D. Flavobacterium meningosepticum bacteremia in an adult with acute leukemia. Use of rifampin to clear persistent infection. Diagn Microbiol Infect Dis 1986;4:65-9.
135. Amoils CP, Shindo ML. Laryngotracheal manifestations of rhinoscleroma. Ann Otol Rhinol Laryngol 1996;105:336-40.
136. Andraca R, Edson RS, Kern EB. Rhinoscleroma: a growing concern in the United States? Mayo Clinic experience. Mayo Clin Proc 1993;68:1151-7.
137. Gamea AM. Local rifampicin in treatment of rhinoscleroma. J Laryngol Otol 1988;102:319-21.
138. Perkins BA, Hamill RJ, Musher DM, O'Hara C. In vitro activities of streptomycin and 11 oral antimicrobial agents against clinical isolates of Klebsiella rhinoscleromatis. Antimicrob Agents Chemother 1992;36:1785-7.
139. Brumfitt W, Dixson S, Hamilton-Miller JMT. Use of rifampin for the treatment of urinary tract infections. Rev Infect Dis 1983;5(suppl 3):S573-82.
140. Stein GE, Gurwith D, Gurwith M. Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections. Antimicrob Agents Chemother 1988;32:802-6.
141. Kosmidis J, Giamarellou H, Papadakis M, Eliades E, Daikos GK. Rifampin in urinary tract infection: a comparison with co-trimoxazole. J Antimicrob Chemother 1983;11:239-44.
142. Bourgault AM, Forward KR, Ronald AR, Harding GK, Thomson M, Grey G. Trimethoprim-rifampin, a new combination agent: efficacy in localized urinary tract infection and influence on microflora. Antimicrob Agents Chemother 1981;19:513-18.
143. Jones RB, Ridgway GL, Boulding S, Hunley KL. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev Infect Dis 1983;5(suppl 3):S556-61.
144. Dawson CR, Hoshiwara I, Daghfous T, Messadi M, Vastine DW, Schachter J. Topical tetracycline and rifampicin therapy of endemic trachoma in Tunisia. Am J Ophthalmol 1975;79:803-11.
145. Coufalik ED, Taylor-Robinson D, Csonka GW. Treatment of nongonococcal urethritis with rifampicin as a means of defining the role of Ureaplasma urealyticum. Br J Vener Dis 1979;55:36-43.
146. Jariwalla AG, Davies BH, White J. Infective endocarditis complicating psittacosis: response to rifampicin. Br Med J 1980;280:155.
147. Oriel JD, Ridgway GL, Goldmeier D, Felmingham D. Treatment of gonococcal urethritis in men a with rifampicin-erythromycin combination. Sex Transm Dis 1982;9:208-11.
148. Belli L, Ambrona MS, Gennaro EA, Isola EH, Rescigno GRG. Acute gonococcal urethritis: treatment with a single dose of rifampicin. J Int Med Res 1983;11:32-7.
149. Morse SA. Chancroid and Haemophilus ducreyi. Clin Microbiol Rev 1989;2:137-57.
150. Plummer FA, Nsanze H, D'Costa LJ, et al. Short-course and single-dose antimicrobial therapy for chancroid in Kenya: studies with rifampin alone and in combination with trimethoprim. Rev Infect Dis 1983;5(suppl 3):S565-72.
151. Fekety R, O'Connor R, Silva J. Rifampin and pseudo-membranous colitis. Rev Infect Dis 1983;5(suppl 3):S524-7.
152. Fu KP, Lasinski ER, Zoganas HC, Kimble EF, Konopka EA. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess. J Antimicrob Chemother 1984;14:633-40.
153. Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987;9:155-9.
154. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-50.
155. Lorber B. Listeriosis. Clin Infect Dis 1997;24:1-11.
156. Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. Clin Microbiol Rev 1997;10:345-57.
157. Graybill JR, Ahrens J. Interaction of rifampin with other antifungal agents in experimental murine candidiasis. Rev Infect Dis 1983;5(suppl 3):S620-5.
158. Medoff G. Antifungal action of rifampin. Rev Infect Dis 1983;5(suppl 3):S614-19.
159. Kissling M, Bergamini N. Rifampin in free combination with other antimicrobial drugs in non-TB infections. Clinical data of 650 patients (a review). Chemotherapy 1981;27:368-402.
160. Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis 1993;16:1-9.
161. Strath M, Scott-Finnigan T, Gardner M, Williamson D, Wilson I. Antimalarial activity of rifampicin in vitro and in rodent models. Trans R Soc Trop Med 1993;87:211-16.
162. Pukrittayakamee S, Viravan C, Charoenlarp C, Yeamput C, Wilson RJM, White NJ. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother 1994;38:511-14.
163. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis J 1994;13:134-40.
164. Megraud F, Bouffant F, Juncas CC. In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994;13:184-6.
165. Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995;35:545-9.